Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
On October 23, 2015, the CHMP gave new advice for doctors and patients in order to minimize the risk of progressive multifocal leukoencephalopathy in patients treated with the multiple sclerosis medicine Tecfidera.
European UnionFood, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.
On October 23, 2015, the CHMP gave new advice for doctors and
patients in order to minimize the risk of progressive multifocal
leukoencephalopathy ("PML") in patients treated with the
multiple sclerosis medicine Tecfidera ("dimethyl
fumarate"). PML is a rare brain infection caused by the John
Cunningham virus. EMA has recommended that a complete blood count
should be performed before starting treatment with Tecfidera and
every three months during treatment. Additionally, a baseline MRI
should be available as a reference (usually within three
months).
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
EMA Issues Recommendations To Minimize Risk Of Rare Brain Infection PML With Tecfidera
European UnionFood, Drugs, Healthcare, Life Sciences
Contributor
Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
